Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM -0.35%72 Equity-to-Asset is 0.35 as of Mar. 2026, which is 22% below its 10-year median of 0.45. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT19.82 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 458 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 58.52% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Orion Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was BDT19,998 Mil. Orion Pharma's Total Assets for the quarter that ended in Mar. 2026 was BDT57,144 Mil.
Therefore, Orion Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.35.
The historical rank and industry rank for Orion Pharma's Equity-to-Asset or its related term are showing as below:
DHA:ORIONPHARM'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35 Med: 0.45 Max: 0.62
Current: 0.35
During the past 12 years, the highest Equity to Asset Ratio of Orion Pharma was 0.62. The lowest was 0.35. And the median was 0.45.
DHA:ORIONPHARM's Equity-to-Asset is ranked worse than 58.52% of 458
companies
in the Utilities - Independent Power Producers industry
Industry Median: 0.41
vs DHA:ORIONPHARM: 0.35
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Orion Pharma Equity-to-Asset Related Terms
Orion Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Equity-to-Asset Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Equity-to-Asset vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Orion Pharma's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Equity-to-Asset of 0.35 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Orion Pharma and its competitors. This is 22% below median its historical median of 0.45. Over the past decade, Orion Pharma's Equity-to-Asset has ranged from 0.35 to 0.62. According to the industry distribution chart, Orion Pharma ranks #268 out of 458 companies in the Utilities - Independent Power Producers industry, placing it in the top 58.5%.
Is Orion Pharma's Equity-to-Asset too high?
Orion Pharma's current Equity-to-Asset of 0.35 is 22% below median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.62. The Utilities - Independent Power Producers industry median Equity-to-Asset is 0.41. Orion Pharma's value of 0.35 is 14.6% below this industry median. Based on the distribution chart, Orion Pharma ranks #268 out of 458 companies in the Utilities - Independent Power Producers industry, which is below the industry midpoint. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Equity-to-Asset compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #268 out of 458 companies for Equity-to-Asset. This places Orion Pharma in the lower half of its industry. The industry median Equity-to-Asset is 0.41. Orion Pharma's value of 0.35 is 14.6% below this benchmark. Historically, Orion Pharma's own Equity-to-Asset has ranged from 0.35 to 0.62 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 0.41, Orion Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for an Utilities - Independent Power Producers company?
The median Equity-to-Asset among Utilities - Independent Power Producers companies is 0.41, based on 458 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Equity-to-Asset of 0.35 is 14.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Equity-to-Asset is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Equity-to-Asset is 0.35, which is 22% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT19.82, compared to a current price of BDT28.60 — trading 44.3% above its estimated fair value. The current Equity-to-Asset is 0.35, which is 22% below median its 10-year median of 0.45 and 14.6% below the Utilities - Independent Power Producers industry median of 0.41. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Equity-to-Asset is 0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.60 is trading 44.3% above its estimated GF Value™ of BDT19.82.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Equity-to-Asset: 0.35 (22% below median its 10-year median of 0.45)
GF Value™: BDT19.82 vs. price of BDT28.60 (44.3% above fair value)
Industry Position: 14.6% below the Utilities - Independent Power Producers median (#268 of 458)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
